Status: Recruiting

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.

Participants needed: 22

Trial details

Phase: Phase 1Age: 2-21Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 24, 2026Locations: 1

Eligibility criteria

Pediatric, adolescent, or young adult patients with relapsed or refractory acute... [+21]

curatively treated non-melanomatous skin cancer, [+12]

Status: Recruiting

A Study of Revumenib and Mezigdomide in People With Leukemia

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

Participants needed: 52

Trial details

Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Jun 22, 2026Locations: 10

Eligibility criteria

Participant must be ≥ 12 years of age at the time of signing the informed consen... [+17]

Participants with acute promyelocytic leukemia [+18]

Status: Recruiting

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain types of genetic mutations (changes).

Participants needed: 22

Trial details

Phase: Phase 1Age: 2-21Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jan 29, 2026Locations: 1

Eligibility criteria

Age ≥ 2 year to 21 years [+8]

Participants who weigh less than 10kg. [+14]